Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma

作者
Abdul Rafae Faisal,Mohammad Faizan,Abdullah Humayun,Zainab Zaib Khan,Ali Shan Hafeez,Asad Zaman,Ahmed Sajid,Pramod Kumar Singh,Henna Qadri,Adib Rahman,Mehtab Anwar,Khutaija Noor,Shahzad Raza
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 7577-7577
标识
DOI:10.1182/blood-2025-7577
摘要

Abstract Introduction Teclistamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, and the first among bispecific antibodies to be approved while talquetamab is an anti-CD3 and anti-GPRC5D bispecific humanized monoclonal antibody for the treatment of patients that have relapsed/refractory multiple myeloma (RRMM). Direct head-to-head analysis of these two drugs with real-world data is limited. We compared the effectiveness and safety of talquetamab and teclistamab in propensity-matched RRMM cohorts. Methods Data for adults with RRMM receiving talquetamab or teclistamab between 25 Oct 2022 and 1 Jan 2025 were extracted from the US Collaborative Network of TriNetX. After exclusions, 229 talquetamab and 643 teclistamab patients were identified; 1:1 propensity-score matching (age, sex, race, comorbidities, renal function, prior therapies) yielded 198 well-balanced patients in both arms. Outcomes were evaluated from day +1 to day +365. Primary endpoints were all-cause mortality and multiple-myeloma (MM) remission. The assessed key secondary endpoints were cytokine release syndrome (CRS), sepsis, pneumonia, thrombocytopenia, hepatotoxicity, immune effector cell–associated neurotoxicity (ICANS), grade ≥3 neutropenia and lymphopenia and acute kidney injury. Moreover, the risk ratios (RR) and hazard ratios (HR) were calculated with 95% confidence intervals (CI). The significance value was set as p<0.05. Results Both of the considered cohorts were comparable. The median age was 67 years and 56% of the total were male participants. For talquetamab, the median follow-up period was 6.1 months (IQR 9.0), while it was 6.2 months (IQR 9.3) for teclistamab. Moreover, in comparison to the cohort of patients on teclistamab that had 42 deaths, 35 deaths were recorded in the talquetamab cohort. Similarly, the 1-year mortality was 21.2% for the former against 17.7% for the latter (RR 0.83, 95 % CI 0.56–1.25; HR 0.87, 95 % CI 0.55–1.36; log-rank p = 0.53). Moreover, MM remission was recorded in 28.3% patients (56/198), as compared to 30.8% (61/198) (RR 0.92, 95 % CI 0.68–1.25; p = 0.58); remission curves overlapped with HR 0.93; log rank p = 0.69. The safety outcomes were also rather similar. Any-grade CRS occurred in 22 out of 104 (21.2%) talquetamab-treated cases, while 21 out of 151 (13.9%) teclistamab-treated patients exhibited it (RR 1.52, 95 % CI 0.88–2.62; p = 0.13); all events were ≤grade 2. ICANS occurred in 9.9% versus 7.4% (RR 1.34; p = 0.42). Grade ≥3 neutropenia was more common with talquetamab (53/198, 26.8 %) than it was with teclistamab (38/198, 19.2 %) and correlated with shorter neutropenia-free survival (HR 1.53, 95 % CI 1.01–2.32; log rank p = 0.04). Severe lymphopenia was recorded in 10 patients per arm (5.1% each). Earlier onset was seen in talquetamab recipients, thus showing a HR of 3.54 (log rank p = 0.04). Furthermore, the incidence of infectious complications favoured talquetamab numerically, with sepsis being 10.1 % versus 13.6 % (RR 0.74; p = 0.28) and pneumonia 15.7 % versus 21.2 % (RR 0.74; p = 0.15). No cases of hepatotoxicity were observed and thrombocytopenia rates were also comparable. Finally, acute kidney injury occurred in 21.7% versus 30.3% (RR 0.72; p = 0.05). Conclusions Within this real-world matched analysis, talquetamab and teclistamab provided similar early survival and remission outcomes for RRMM, with broadly overlapping toxicity profiles. Talquetamab was associated with higher early-onset neutropenia yet showed numerically fewer serious infections, whereas CRS and ICANS remained low-grade for both agents. Bispecific antibody selection decision should weigh in baseline marrow reserve and infection risk until longer follow-up clarifies durability and late-onset toxicities.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
初染完成签到,获得积分10
刚刚
酷波er的应助被HYH采纳,获得10
刚刚
yinyin发布了新的文献求助20
1秒前
1秒前
儒雅一凤发布了新的文献求助10
2秒前
汉堡包的应助被称心青亦采纳,获得10
2秒前
Ming发布了新的文献求助10
2秒前
无花果的应助被刘泓采纳,获得10
3秒前
初染发布了新的文献求助10
3秒前
3秒前
zzy完成签到,获得积分10
5秒前
5秒前
月下完成签到 ,获得积分10
6秒前
刘谋完成签到,获得积分10
6秒前
6秒前
7秒前
kiwi发布了新的文献求助10
7秒前
7秒前
义气的雪糕完成签到,获得积分10
7秒前
8秒前
天天快乐的应助被野性的苗条采纳,获得10
8秒前
妮妮发布了新的文献求助10
8秒前
9秒前
9秒前
renn发布了新的文献求助10
10秒前
zhu完成签到,获得积分10
10秒前
胡唯完成签到 ,获得积分10
10秒前
情怀的应助被科研通管家采纳,获得10
10秒前
无花果的应助被科研通管家采纳,获得10
10秒前
CodeCraft的应助被科研通管家采纳,获得10
10秒前
深情安青的应助被科研通管家采纳,获得10
10秒前
Akim的应助被科研通管家采纳,获得10
10秒前
Maestro_S的应助被科研通管家采纳,获得10
10秒前
李健的应助被科研通管家采纳,获得10
11秒前
汉堡包的应助被科研通管家采纳,获得10
11秒前
完美世界的应助被科研通管家采纳,获得10
11秒前
11秒前
小二郎的应助被xiaoxuey采纳,获得10
11秒前
彭于晏的应助被科研通管家采纳,获得10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183923
求助须知:如何正确求助?哪些是违规求助? 9573132
关于积分的说明 21829461
捐赠科研通 7781024
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558333
邀请新用户注册赠送积分活动 2480648